Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study
Top Cited Papers
Open Access
- 18 November 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 49 (2), 271-280
- https://doi.org/10.1093/rheumatology/kep093
Abstract
Objective. To assess the efficacy of rituximab (RTX) in SSc. Methods. Fourteen patients with SSc were evaluated. Eight patients were randomized to receive two cycles of RTX at baseline and 24 weeks [each cycle consisted of four weekly RTX infusions (375 mg/m2)] in addition to standard treatment, whereas six patients (control group) received standard treatment alone. Lung involvement was assessed by pulmonary function tests (PFTs) and chest high-resolution CT (HRCT). Skin involvement was assessed both clinically and histologically. Results. There was a significant increase of forced vital capacity (FVC) in the RTX group compared with baseline (mean ± s.d.: 68.13 ± 19.69 vs 75.63 ± 19.73, at baseline vs 1-year, respectively, P = 0.0018). The median percentage of improvement of FVC in the RTX group was 10.25%, whereas that of deterioration in the controls was 5.04% (P = 0.002). Similarly, diffusing capacity of carbon monoxide (DLCO) increased significantly in the RTX group compared with baseline (mean ± s.d.: 52.25 ± 20.71 vs 62 ± 23.21, at baseline vs 1-year respectively, P = 0.017). The median percentage of improvement of DLCO in the RTX group was 19.46%, whereas that of deterioration in the control group was 7.5% (P = 0.023). Skin thickening, assessed with the Modified Rodnan Skin Score (MRSS), improved significantly in the RTX group compared with the baseline score (mean ± s.d.: 13.5 ± 6.84 vs 8.37 ± 6.45 at baseline vs 1-year, respectively, P < 0.001). Conclusion. Our results indicate that RTX may improve lung function in patients with SSc. To confirm our encouraging results we propose that larger scale, multicentre studies with longer evaluation periods are needed.This publication has 44 references indexed in Scilit:
- B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosisArthritis & Rheumatism, 2009
- Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological studyAnnals Of The Rheumatic Diseases, 2008
- Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2007
- High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot studyBlood, 2007
- The EUSTAR model for teaching and implementing the modified Rodnan skin score in systemic sclerosisAnnals Of The Rheumatic Diseases, 2007
- Rituximab is effective for extensive steroid-refractory chronic graft-vs.-host-diseaseLeukemia & Lymphoma, 2007
- B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic SclerosisThe American Journal of Pathology, 2006
- Chronic Graft-Versus-Host DiseaseDrugs, 2006
- Is systemic sclerosis an antigen‐driven T cell disease?Arthritis & Rheumatism, 2004
- Microchimerism and HLA-compatible relationships of pregnancy in sclerodermaThe Lancet, 1998